===
EQS-Ad-hoc: Merck KGaA / Key word(s): Study results
Merck KGaA: Phase III trials of xevinapant in locally advanced head & neck cancer discontinued
24-Jun-2024 / 19:00 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News
- a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
Disclosure of inside information pursuant to Article 17 of Regulation (EU) No 596/2014
Merck KGaA: Phase III trials of xevinapant in locally advanced head & neck cancer discontinued
Darmstadt, June 24, 2024: Merck KGaA is investigating a treatment of xevinapant plus platinum-based chemotherapy (CRT),
compared to placebo plus CRT, in patients with unresected locally advanced head and neck cancer in a phase III clinical
trial (TrilynX). The company decided to discontinue this study. The decision follows a pre-planned interim analysis
performed by the study's Independent Data Monitoring Committee, which found that the trial would be unlikely to meet
its primary objective of prolonging event-free survival. Given the totality of the data, the company decided to also
stop the phase III clinical trial X-Ray Vision (xevinapant plus radiotherapy, compared to placebo plus radiotherapy in
patients who underwent resection of locally advanced head and neck cancer).

Xevinapant is currently under clinical investigation and not approved for any indication anywhere in the world.
Esther Döringer
Merck KGaA
Frankfurter Straße 250
64293 Darmstadt
Germany
Phone: +49 151 1454 7809
Email: esther.doeringer@merckgroup.com
Internet: https://www.merckgroup.com/en
ISIN: DE0006599905
WKN: 659990
Indices: DAX
Stock exchanges: Regulated Market of Frankfurt am Main (Prime Standard); Open Markets of Berlin, Düsseldorf, Hamburg,
Hanover, Munich, Stuttgart; EUREX derivatives exchange; London, SIX
Contact:
Esther Döringer, Head of Media Relations
End of Inside Information
24-Jun-2024 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press
Releases.

Archive at www.eqs-news.com  
Language:     English 
Company:      Merck KGaA 

Frankfurter Str. 250
64293 Darmstadt
Germany

Phone:        +49 (0)6151 72 - 2702 
E-mail:       Friederike.Segeberg@merckgroup.com 
Internet:     https://www.merckgroup.com/de 
ISIN:         DE0006599905 
WKN:          659990 
Indices:      DAX 
Listed:       Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, 

Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; London, SIX
EQS News ID: 1931843

End of Announcement EQS News Service
===
1931843 24-Jun-2024 CET/CEST

Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1931843&application_name=news

END) Dow Jones Newswires

June 24, 2024 13:00 ET (17:00 GMT)